{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:13:36Z","timestamp":1707524016158},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"DOI":"10.7759\/cureus.44542","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T19:48:08Z","timestamp":1693597688000},"source":"Crossref","is-referenced-by-count":0,"title":["CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Tyler","family":"D'Ovidio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matko","family":"Kalac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel RL","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020, 70:7-30. 10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-90. 10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton LM","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006, 107:265-76. 10.1182\/blood-2005-06-2508","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1590.1590","article-title":"B cell lymphoma in association with multiple myeloma: analysis of the biologic relationship","volume":"118","author":"Mahindra AK","year":"2011","unstructured":"Mahindra AK, Sohani AR, Toomey CE, et al.. B cell lymphoma in association with multiple myeloma: analysis of the biologic relationship. Blood. 2011, 118:1590. 10.1182\/blood.V118.21.1590.1590","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2017.53.11.2725754","article-title":"Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia","volume":"53","author":"Liu Y","year":"2017","unstructured":"Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc). 2017, 53:597-608. 10.1358\/dot.2017.53.11.2725754","journal-title":"Drugs Today (Barc)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke FL","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al.. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019, 20:31-42. 10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE- 1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM)","volume":"134","author":"Madduri D","year":"2019","unstructured":"Madduri D, Usmani SZ, Jagannath S, et al.. Results from CARTITUDE- 1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R MM). Blood. 2019, 134:577. 10.1182\/blood-2019-121731","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al.. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021, 384:705-16. 10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje N","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al.. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019, 380:1726-37. 10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:e538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo A","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al.. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015, 33:2863-9. 10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson BD","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, et al.. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016, 128:2489-96. 10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee DW","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al.. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014, 124:188-95. 10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee DW","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al.. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019, 25:625-38. 10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2568","article-title":"The acceleration of CAR-T therapy in non-Hodgkin lymphoma","volume":"37","author":"Munshi PN","year":"2019","unstructured":"Munshi PN, Ujjani C. The acceleration of CAR-T therapy in non-Hodgkin lymphoma. Hematol Oncol. 2019, 37:233-9. 10.1002\/hon.2568","journal-title":"Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip T","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al.. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995, 333:1540-5. 10.1056\/NEJM199512073332305","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14453","article-title":"Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era","volume":"176","author":"Vardhana SA","year":"2017","unstructured":"Vardhana SA, Sauter CS, Matasar MJ, et al.. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 2017, 176:591-9. 10.1111\/bjh.14453","journal-title":"Br J Haematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin Q","year":"2019","unstructured":"Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer. 2019, 18:154. 10.1186\/s12943-019-1092-1","journal-title":"Mol Cancer"},{"key":"ref19","unstructured":"Pennsylvania Uo, Novartis. up-front CART-BCMA with or without huCART19 in high-risk multiple myeloma. (2018). https:\/\/ClinicalTrials.gov\/show\/NCT03549442."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12910","article-title":"Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma","volume":"92","author":"Feng D","year":"2020","unstructured":"Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma. Scand J Immunol. 2020, 92:e12910. 10.1111\/sji.12910","journal-title":"Scand J Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter T","year":"2019","unstructured":"Nerreter T, Letschert S, G\u00f6tz R, et al.. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun. 2019, 10:3137. 10.1038\/s41467-019-10948-w","journal-title":"Nat Commun"},{"key":"ref22","unstructured":"CART-19 for multiple myeloma. (2014). https.\/\/ClinicalTrials.gov\/show\/NCT02135406."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019739","article-title":"Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy","volume":"99","author":"Li T","year":"2020","unstructured":"Li T, Tan J, Chen L, et al.. Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy. Medicine (Baltimore). 2020, 99:e19739. 10.1097\/MD.0000000000019739","journal-title":"Medicine (Baltimore)"},{"key":"ref24","article-title":"Nodal marginal zone lymphoma","author":"Campo E","year":"2017","unstructured":"Campo E, Nathwani BN, Pileri SA, Stein H, Jaffe ES, Muller-Hermelink HK. Nodal marginal zone lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al. (ed): IARC Publications, Lyon, France; 2017. 4:263."},{"key":"ref25","article-title":"Plasmablastic lymphoma","author":"Campo E","year":"2017","unstructured":"Campo E, Nathwani BN, Pileri SA, Stein H, Jaffe ES, Muller-Hermelink HK. Plasmablastic lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al. (ed): IARC Publications, Lyon, France; 2017. 4:321."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/111566-cd19-targeted-chimeric-antigen-receptor-t-cell-therapy-for-concomitant-diffuse-large-b-cell-lymphoma-and-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:58:53Z","timestamp":1707508733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/111566-cd19-targeted-chimeric-antigen-receptor-t-cell-therapy-for-concomitant-diffuse-large-b-cell-lymphoma-and-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.44542","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}